Click Therapeutics, Inc., which provides digital prescription medical treatments, closed a $52 million Series B funding round. Proceeds from the Series B financing will be used to accelerate the development and commercialization of Click’s internal prescription digital therapeutic pipeline and advance Click’s platform capabilities.
The round was led by new investors H.I.G. BioHealth Partners and Accelmed Partners II, with participation from Health Catalyst Capital, Revelation Partners, and a top biotechnology hedge fund, and from existing investors Sanofi Ventures, K2 HealthVentures, Hikma Ventures, and Ridgetop Health. In conjunction with the Series B financing, Click’s Board of Directors will expand to include Alex Zisson, managing director at H.I.G. BioHealth, and Dr. Uri Geiger, founder and managing partner of Accelmed.
Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments for patients with unmet medical needs. Its Clickometrics® adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes. Click’s lead prescription program has recently entered a pivotal, fully remote, randomized, controlled trial on the Verily platform for the treatment of major depressive disorder (MDD) in up to 540 adults. Click’s pipeline of innovative digital therapeutics spans multiple therapeutic areas, from psychiatry and chronic pain to cardiometabolic and autoimmune disorders. In addition to its internal pipeline programs, Click has entered into landmark collaboration agreements with Otsuka to develop and commercialize a prescription digital therapeutic for treatment of MDD, and with Boehringer Ingelheim to develop and commercialize a prescription-based digital therapeutic to aid in the treatment of schizophrenia.
H.I.G. BioHealth Partners is the dedicated life-science investment affiliate of H.I.G. Capital. H.I.G. BioHealth Partners invests in a broad range of healthcare opportunities across sectors and stages, principally in companies developing therapeutic drugs, medical devices, and diagnostics for significant unmet medical needs. With approximately $400 million in committed capital, H.I.G. BioHealth Partners invests $5 million to $40 million per company over the life of an investment.
Accelmed is a U.S.-based private equity firm focused on acquiring and investing in U.S. commercial stage, lower middle market health technology companies. Since 2009, Accelmed has deployed over $400 million into companies spanning medical devices, diagnostics, digital health, and technology-enabled health care services.
This was reported by Click Therapeutics, Inc. on October 22, 2021.
Contact information: Daniel Busby, Vice President, Investor Relations & Strategic Finance, Click Therapeutics, Inc., 80 White Street, New York, NY 10013; Email: firstname.lastname@example.org; Website: https://www.clicktherapeutics.com/